198棋牌官网下载-手机版APP下载

Details

NBD AI Bulletin-?LBX Pharmacy Chain Joint Stock Company (SH 603883, close price: 70.8 yuan) announced on November 13 that the company has decided to appoint Mr. Guan Wenti as vice president who has been nominated by the company's president Ms. Wang Li and the board of directors and reviewed by the?remuneration and appraisal committee.

The semiannual report 2020 shows that the main business of LBX Pharmacy Chain is pharmaceutical retail, pharmaceutical wholesale, and others, accounting for 84.66%, 14.47%, 0.86% of revenue, respectively.

(By Gao Han)

Disclaimer: The content and data of this article are for reference only and do not constitute investment advice. Please verify before use. Any action you take upon the information on this website is at your own risk.

Details

NBD AI Bulletin -?Tasly Pharmaceutical Group Co Ltd ("the Company", SH 600535, closing price: 17.18 Yuan) announced on the evening of November 13 that shareholder?Tasly Holding Group has released the pledge of its 37 million circulating shares without restrictions on the sale and pledged 76.33 million shares to Citic Securities.?

As of the date of this announcement,?Tasly Holding Group and its six persons acting in concert holds a total of 754 million shares in Tasly Pharmaceutical Group Co Ltd, accounting for 49.88% of the latter's total equity, with the former itself holding 683 million shares, about 45.18% of the listed company's total equity. After the release of the pledge and re-pledge, Tasly Holding Group has accumulatively pledged 282 million shares, representing 41.31% of its holdings or 18.66% of the listed company's total equity.?

The semi-annual report shows that Tasly Pharmaceutical Group Co Ltd mainly engages in?pharmaceutical commerce, pharmaceutical industry, accounting for 64.51% and 34.67% of its revenue, respectively.

Tasly Pharmaceutical Group Co Ltd's chairman is Yan Kaijing, 41 years old, bachelor's degree in computer and information technology at Aston University in the United Kingdom, bachelor's degree in international securities, investment and banking at University of Reading in the United Kingdom, and Ph.D. in traditional Chinese pharmacology at Tianjin University of Traditional Chinese Medicine. Tasly Pharmaceutical Group Co Ltd's general manager is Su Jing, male, 57 years old, graduated from Zhongshan School of Medicine, Sun Yat-sen University.

Tips on "Stock Trends":

1. The number of shares held by northbound investors in the Company decreased by 425,800 in the past 30 days, representing 0.02% of the Company's circulating shares;

2. There was no institutional research on the Company in the past 30 days.?

(By Lan Suying)

Disclaimer: The content and data of this article are for reference only and do not constitute investment advice. Please verify before use. Any action you take upon the information on this website is at your own risk.

Details

NBD AI Bulletin-?Beijing Sinnet Technology Co, Ltd (SZ 300383, close price: 19.81 yuan) announced on late November 13 that the company's shareholders Yuan Ding, Li Chao, Gao Hong, Hou Yan, Chen Hao has completed the reduction of about?790,000 shares, accounting for 0.0508% of the total equity of the company.

The 2019 annual report shows that the main business of Beijing Sinnet Technology is telecommunications services and others, accounting for 98.99% and 0.82% of the revenue, respectively.

(By Gao Han)

Disclaimer: The content and data of this article are for reference only and do not constitute investment advice. Please verify before use. Any action you take upon the information on this website is at your own risk.

Details

NBD AI Bulletin -?China TransInfo Technology Co Ltd ("the Company", SZ 002373, closing price: 20.67 yuan) announced on the evening of November 13 that it has been noticed that shareholder?China TransInfo Technology Corp. has partially pledged its holdings of the Company's shares. On November 12, 2020, the shareholder pledged 26 million shares, accounting for 18.93% of its holdings.?As of the date of this announcement, shareholder Xia Shudong has accumulatively pledged 107 million shares, representing around 44.43% of his holdings, while shareholder Xia Shufeng has accumulatively pledged 6.13 million shares, accounting for around 28.16% of his holdings.

The semi-annual report shows that China TransInfo Technology Co Ltd mainly engages in smart transportation, intelligent security, accounting for 52.74% and 47.26% of its revenue, respectively.

China TransInfo Technology Co Ltd's chairman is Xia Shudong, male, 48 years old, Peking University PhD. China TransInfo Technology Co Ltd's general manager is Pan Fan, male, 38 years old, bachelor's degree in automation at Huazhong University of Science and Technology, EMBA candidate at Tsinghua PBCSF.

Tips on "Stock Trends":

1. The number of shares held by northbound investors in the Company increased by 884,300 in the past 30 days, representing 0.09% of the Company's circulating shares;

2. There was no institutional research on the Company in the past 30 days.

(By Lan Suying)

Disclaimer: The content and data of this article are for reference only and do not constitute investment advice. Please verify before use. Any action you take upon the information on this website is at your own risk.

Details

NBD AI Bulletin-?Wuxi Taiji Industry?Corporation Limited (SH 600667, close price: 10.74 yuan) announced on late November 13 that the company received a notice from its subsidiary, IT Electronics Eleventh Design & Research Institute Scientific and Technology. The subsidiary has won bidding for the 300 wafer production line of Zhejiang Haixin Micro-semiconductor Technology Co., Ltd and has signed the contract with the latter.

The semiannual report 2020 shows that the main business of Wuxi Taiji Industry Corporation Limited is engineering and technical services, semiconductors, photovoltaic power generation, inter-division offsetting, accounting for 71.06%, 25.79%, 2.78%, -0.1% of the revenue, respectively.

(By Gao Han)

Disclaimer: The content and data of this article are for reference only and do not constitute investment advice. Please verify before use. Any action you take upon the information on this website is at your own risk.